11 May 2021

Statement on AstraZeneca’s continued support for the people of India

 

The COVID-19 pandemic continues to cause devastation around the world, with India currently facing an incredible humanitarian crisis from a surge of COVID-19 cases and related deaths.

To date, approximately 10% of India’s population of 1.3 billion has received one dose of our vaccine – accounting for 90% of all vaccinations. Our partner in India, Serum Institute of India (SII), already produces more COVID-19 vaccine doses than any other organisation globally.

Access to COVID-19 vaccination is a critical component in tackling the pandemic, in India and beyond. It is why we have devoted our time, resources, and energy to develop a vaccine that is available at no profit during the pandemic and supplied equitably to as many people as possible.

Today, AstraZeneca pledges $1 million USD in humanitarian aid to support relief activities in India as well as other communities around the world hardest hit by the pandemic. This includes directing $250,000 USD to Direct Relief to support their relief efforts in India, which includes the distribution of oxygen concentrators, medicines, other supplies and personal protective equipment (PPE) to provide treatment and care for those with COVID-19.

Adar Poonawalla, CEO, SII, said, “We thank AstraZeneca for their unwavering support. We are working together to scale up and committed to provide more vaccines to India by July. This will help us to protect countless lives against this devastating virus.”

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “We remain steadfast in our continued commitment to changing the course of the pandemic for the people of India. We hope that through increasing vaccinations, humanitarian relief efforts, and critical donations of medicines and needed equipment, India will steadily recover from this crisis. We stand united with the people of India, as we work tirelessly to bring this pandemic to an end as quickly as possible.”

    • Facebook
    • Twitter
    • Linkedin
    • Facebook
  • Share
 

Loading......